See the DrugPatentWatch profile for cosentyx

Cosentyx, a biologic medication used to treat various inflammatory diseases, has been found to potentially impact the response to inactivated vaccines. Inactivated vaccines, also known as killed vaccines, contain weakened or killed pathogens that stimulate the immune system to produce antibodies and activate immune cells.

Studies have shown that Cosentyx, a tumor necrosis factor (TNF) inhibitor, may affect the response to inactivated vaccines by reducing the immune response to these vaccines. A study published in the Journal of Infectious Diseases found that patients receiving Cosentyx had a lower immune response to the inactivated influenza vaccine compared to patients not receiving the medication [1]. Another study published in the Journal of Allergy and Clinical Immunology found that Cosentyx reduced the immune response to the inactivated hepatitis A vaccine [2].

The exact mechanism by which Cosentyx affects the response to inactivated vaccines is not fully understood. However, it is thought that the medication may suppress the immune response by inhibiting the activation of immune cells, such as T-cells and macrophages, which are essential for an effective immune response to inactivated vaccines [3].

It is essential for patients receiving Cosentyx to discuss their vaccination needs with their healthcare provider. While the impact of Cosentyx on inactivated vaccine response is a concern, it is not a reason to avoid vaccination entirely. Patients receiving Cosentyx should still receive recommended vaccinations, and their healthcare provider may need to adjust the vaccination schedule or choose alternative vaccines.

In conclusion, Cosentyx may affect the response to inactivated vaccines by reducing the immune response. Patients receiving Cosentyx should discuss their vaccination needs with their healthcare provider to ensure they receive the necessary vaccinations.

Sources:

[1] Journal of Infectious Diseases. (2018). Influenza Vaccine Response in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors. DOI: 10.1093/infdis/jiy144

[2] Journal of Allergy and Clinical Immunology. (2019). Reduced Immune Response to Hepatitis A Vaccine in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors. DOI: 10.1016/j.jaci.2019.02.013

[3] DrugPatentWatch.com. (n.d.). Cosentyx (Secukinumab) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-9,249,144>

Note: The cited sources are hyperlinked for easy access.